Patents by Inventor BRENTON PAOLELLA

BRENTON PAOLELLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC TARGETING OF PHOSPHATE DYSREGULATION IN CANCER VIA THE XPR1:KIDINS220 PROTEIN COMPLEX
    Publication number: 20230277618
    Abstract: The subject matter disclosed herein is generally directed to inhibition of XPR1 :KIDINS220-mediated phosphate export to treat cancer, in particular, ovarian and uterine cancers. The subject matter disclosed herein is also generally directed to determining cancer dependency on phosphate export by detecting the expression of SLC34A2. Compositions for inhibiting XPR1 :KIDINS220-mediated phosphate export are also described.
    Type: Application
    Filed: August 9, 2021
    Publication date: September 7, 2023
    Inventors: Todd Golub, Daniel Bondeson, Brenton Paolella, Francisca Vazquez
  • COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA
    Publication number: 20230181528
    Abstract: The disclosure is directed to compositions and methods that are useful for the treatment of a neoplasia. Specifically, methods for inducing cell death or reducing cell survival of a neoplastic cell (e.g., rhabomyosarcoma) and methods of treating a subject having a neoplasia characterized by a loss of VPS4 expression are disclosed.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 15, 2023
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Andrew AGUIRRE, Brenton PAOLELLA, Francisca VAZQUEZ, Jasper Edgar NEGGERS
  • RAPID PREDICTION OF DRUG RESPONSIVENESS
    Publication number: 20220340976
    Abstract: The present disclosure relates to compositions and methods for rapid prediction, based upon early single cell transcriptomic assessment of a biopsied sample obtained from a subject, of whether a subject will be responsive to a drug.
    Type: Application
    Filed: September 1, 2020
    Publication date: October 27, 2022
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Andrew J. Aguirre, Francisca Vazquez, Aviad Tsherniak, James McFarland, Brenton Paolella
  • SF3B1 SUPPRESSION AS A THERAPY FOR TUMORS HARBORING SF3B1 COPY LOSS
    Publication number: 20190147975
    Abstract: The present invention provides an association between copy loss of SF3B1 in cancer and sensitivity to SF3B1 suppression. Cancer cells harboring partial SF3B1 copy-loss are more sensitive because they lack a reservoir of SF3b complex that protects cells with normal SF3B1 copy number from cell death upon SF3B1 suppression. The invention also provides methods for treating cancer, especially cancer with SF3B1 copy loss, by suppressing the expression or activity of SF3B1.
    Type: Application
    Filed: April 7, 2017
    Publication date: May 16, 2019
    Inventors: RAMEEN BEROUKHIM, BRENTON PAOLELLA, WILLIAM J. GIBSON